Top Page
Omega Diagnostics
(LSE:CNSL)
Omega Diagnostics (CNSL) vs. iShares MSCI United Kingdom ETF (EWC)
Omega Diagnostics Business Overview & Revenue Model
Omega Diagnostics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.33M | 8.33M | 9.77M | 7.55M | 8.54M | 6.82M |
| Gross Profit | 5.00M | 5.00M | 6.05M | 3.17M | 4.75M | 4.00M |
| EBITDA | 2.20M | 2.20M | -73.00K | -2.65M | -382.00K | 418.00K |
| Net Income | 1.57M | 1.57M | -328.00K | -3.86M | -11.33M | -2.10M |
Balance Sheet | ||||||
| Total Assets | 13.80M | 13.80M | 13.89M | 14.40M | 17.84M | 29.55M |
| Cash, Cash Equivalents and Short-Term Investments | 4.87M | 4.87M | 5.44M | 5.12M | 1.60M | 5.83M |
| Total Debt | 349.00K | 349.00K | 148.00K | 74.00K | 370.00K | 2.84M |
| Total Liabilities | 2.39M | 2.39M | 4.21M | 4.45M | 6.02M | 6.16M |
| Stockholders Equity | 11.41M | 11.41M | 9.68M | 9.95M | 11.82M | 23.38M |
Cash Flow | ||||||
| Free Cash Flow | -142.00K | -142.00K | 548.00K | -3.31M | -4.71M | -5.24M |
| Operating Cash Flow | 83.00K | 83.00K | 607.00K | -3.15M | -3.23M | -2.42M |
| Investing Cash Flow | 2.12M | 2.12M | -2.51M | 5.18M | -493.00K | -2.83M |
| Financing Cash Flow | -251.00K | -251.00K | -265.00K | 1.49M | -502.00K | 11.07M |
Omega Diagnostics Technical Analysis
Omega Diagnostics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | £173.32M | 26.08 | 20.31% | 3.77% | 10.80% | 1.75% | |
65 Neutral | £110.44M | 19.26 | 8.71% | ― | -1.43% | 28.57% | |
58 Neutral | £7.91M | 1,275.00 | 0.08% | ― | 87.72% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £6.31M | 4.02 | 14.85% | ― | -14.77% | ― | |
49 Neutral | £3.75M | ― | -105.98% | ― | -25.05% | -5.74% |
Omega Diagnostics Corporate Events
Cambridge Nutritional Sciences reported a decrease in revenue for the first half of 2025, with sales dropping to £3.9 million from £4.1 million in the same period last year. Despite this, the company achieved an improved gross margin of 67.7% due to production efficiencies and a favorable product mix. The company has restructured its sales and marketing teams to focus on long-term growth, particularly in regions where sales have lagged, such as mainland Europe. While the company expects full-year sales to be lower than the previous year, it remains confident in its strategic objectives, supported by a strong cash position and ongoing investments in new initiatives.
The most recent analyst rating on (GB:CNSL) stock is a Hold with a £3.00 price target. To see the full list of analyst forecasts on Omega Diagnostics stock, see the GB:CNSL Stock Forecast page.
Cambridge Nutritional Sciences plc has announced it will release its Half Year results for the six months ended 30 September 2025 on 10 November 2025. The company will host a live online presentation for shareholders and potential investors on the same day to discuss the results, providing an opportunity for engagement and transparency with stakeholders.
The most recent analyst rating on (GB:CNSL) stock is a Hold with a £3.00 price target. To see the full list of analyst forecasts on Omega Diagnostics stock, see the GB:CNSL Stock Forecast page.
Cambridge Nutritional Sciences plc has announced the finalization of its Notice of Annual General Meeting and the Annual Report and Accounts for the year ending March 31, 2025. The AGM is scheduled for September 25, 2025, and the Annual Report will be distributed to shareholders and made available on the company’s website. This announcement underscores the company’s commitment to transparency and engagement with its stakeholders.
Cambridge Nutritional Sciences Plc has announced the granting of share options to Ajay Patel, the Chief Financial Officer and Executive Director. The grant includes 1,200,000 options over ordinary shares, which are subject to specific time conditions and Ajay Patel’s continued role as a director. This move is part of the company’s ongoing efforts to align executive incentives with shareholder interests, potentially impacting the company’s operational focus and market positioning.
Cambridge Nutritional Sciences PLC reported its final results for the year ending March 31, 2025, highlighting a 12.7% increase in total income to £11.1 million, despite a 14.8% drop in revenues. The company achieved a significant improvement in gross margin to 65.3% and a 310% growth in profit before taxation. Operational improvements, including enhanced productivity and reduced scrap yields, have been pivotal in driving these financial gains. The company has also strengthened its leadership team and invested in automation to boost productivity and reduce costs. The strategic focus on core products and markets, along with a commitment to distributor partnerships and practitioner education, has positioned the company for future growth. The leadership changes, including the appointment of a new CEO and other key roles, are expected to further drive the company’s transformation and market expansion.